Nextage Therapeutics Stock Revenue
MCTC Stock | ILA 37.70 1.30 3.33% |
Nextage Therapeutics fundamentals help investors to digest information that contributes to Nextage Therapeutics' financial success or failures. It also enables traders to predict the movement of Nextage Stock. The fundamental analysis module provides a way to measure Nextage Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nextage Therapeutics stock.
Nextage |
Nextage Revenue Analysis
Nextage Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Nextage Therapeutics Revenue | 297 K |
Most of Nextage Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nextage Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition |
Based on the latest financial disclosure, Nextage Therapeutics reported 297 K of revenue. This is 100.0% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The revenue for all Israel stocks is 100.0% higher than that of the company.
Nextage Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nextage Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nextage Therapeutics could also be used in its relative valuation, which is a method of valuing Nextage Therapeutics by comparing valuation metrics of similar companies.Nextage Therapeutics is currently under evaluation in revenue category among related companies.
Nextage Fundamentals
Return On Asset | -0.37 | |||
Profit Margin | (2.30) % | |||
Operating Margin | (9.71) % | |||
Shares Outstanding | 2.27 M | |||
Shares Owned By Insiders | 22.39 % | |||
Shares Owned By Institutions | 0.02 % | |||
Price To Earning | (91.98) X | |||
Price To Book | 4.68 X | |||
Price To Sales | 26.11 X | |||
Revenue | 297 K | |||
Gross Profit | 207 K | |||
EBITDA | (5.38 M) | |||
Net Income | (2.09 M) | |||
Cash And Equivalents | 358 K | |||
Cash Per Share | 0.16 X | |||
Debt To Equity | 65.70 % | |||
Current Ratio | 0.44 X | |||
Book Value Per Share | 0.90 X | |||
Cash Flow From Operations | (5 M) | |||
Earnings Per Share | (0.24) X | |||
Beta | 1.05 | |||
Market Capitalization | 9.54 M | |||
Total Asset | 6.01 M | |||
Retained Earnings | (103 M) | |||
Working Capital | 1000 K | |||
Current Asset | 3 M | |||
Current Liabilities | 2 M | |||
Z Score | -23.8 | |||
Net Asset | 6.01 M |
About Nextage Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nextage Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nextage Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nextage Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Micromedic Technologies Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. Further, the company provides diagnostic solutions for multiple cancer diagnostic applications. MICROMEDIC TECHNOL operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Nextage Therapeutics Piotroski F Score and Nextage Therapeutics Altman Z Score analysis. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Nextage Stock analysis
When running Nextage Therapeutics' price analysis, check to measure Nextage Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nextage Therapeutics is operating at the current time. Most of Nextage Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nextage Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nextage Therapeutics' price. Additionally, you may evaluate how the addition of Nextage Therapeutics to your portfolios can decrease your overall portfolio volatility.
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |